JP2015522569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522569A5 JP2015522569A5 JP2015518611A JP2015518611A JP2015522569A5 JP 2015522569 A5 JP2015522569 A5 JP 2015522569A5 JP 2015518611 A JP2015518611 A JP 2015518611A JP 2015518611 A JP2015518611 A JP 2015518611A JP 2015522569 A5 JP2015522569 A5 JP 2015522569A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigen
- allergen
- particles
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000013566 allergen Substances 0.000 claims 8
- 102000008214 Glutamate decarboxylase Human genes 0.000 claims 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 235000013336 milk Nutrition 0.000 claims 2
- 239000008267 milk Substances 0.000 claims 2
- 210000004080 milk Anatomy 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims 1
- 102000009366 Alpha-s1 casein Human genes 0.000 claims 1
- 108050000244 Alpha-s1 casein Proteins 0.000 claims 1
- 244000144730 Amygdalus persica Species 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 1
- 244000205479 Bertholletia excelsa Species 0.000 claims 1
- 235000012284 Bertholletia excelsa Nutrition 0.000 claims 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 1
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 240000009226 Corylus americana Species 0.000 claims 1
- 235000001543 Corylus americana Nutrition 0.000 claims 1
- 235000007466 Corylus avellana Nutrition 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 claims 1
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 claims 1
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 101000883515 Homo sapiens Chitinase-3-like protein 1 Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 102000047918 Myelin Basic Human genes 0.000 claims 1
- 101710107068 Myelin basic protein Proteins 0.000 claims 1
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 claims 1
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 claims 1
- 102000007999 Nuclear Proteins Human genes 0.000 claims 1
- 108010089610 Nuclear Proteins Proteins 0.000 claims 1
- 108010058846 Ovalbumin Proteins 0.000 claims 1
- 241001330451 Paspalum notatum Species 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000016202 Proteolipids Human genes 0.000 claims 1
- 108010010974 Proteolipids Proteins 0.000 claims 1
- 235000006040 Prunus persica var persica Nutrition 0.000 claims 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
- 101800001271 Surface protein Proteins 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 102000005937 Tropomyosin Human genes 0.000 claims 1
- 108010030743 Tropomyosin Proteins 0.000 claims 1
- 102000034337 acetylcholine receptors Human genes 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 229940098773 bovine serum albumin Drugs 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012645 endogenous antigen Substances 0.000 claims 1
- 102000005525 fibrillarin Human genes 0.000 claims 1
- 108020002231 fibrillarin Proteins 0.000 claims 1
- -1 fp130-RAPS Proteins 0.000 claims 1
- 210000003780 hair follicle Anatomy 0.000 claims 1
- 102000054350 human CHI3L1 Human genes 0.000 claims 1
- 230000000521 hyperimmunizing effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229940092253 ovalbumin Drugs 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261662687P | 2012-06-21 | 2012-06-21 | |
| US61/662,687 | 2012-06-21 | ||
| PCT/US2013/047079 WO2013192532A2 (en) | 2012-06-21 | 2013-06-21 | Peptide conjugated particles |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019016132A Division JP7210306B2 (ja) | 2012-06-21 | 2019-01-31 | ペプチドコンジュゲート粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522569A JP2015522569A (ja) | 2015-08-06 |
| JP2015522569A5 true JP2015522569A5 (enExample) | 2017-11-09 |
| JP6557140B2 JP6557140B2 (ja) | 2019-08-07 |
Family
ID=49769721
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518611A Active JP6557140B2 (ja) | 2012-06-21 | 2013-06-21 | ペプチドコンジュゲート粒子 |
| JP2019016132A Active JP7210306B2 (ja) | 2012-06-21 | 2019-01-31 | ペプチドコンジュゲート粒子 |
| JP2021095735A Active JP7491869B2 (ja) | 2012-06-21 | 2021-06-08 | ペプチドコンジュゲート粒子 |
| JP2023118971A Pending JP2023153869A (ja) | 2012-06-21 | 2023-07-21 | ペプチドコンジュゲート粒子 |
| JP2025116638A Pending JP2025163048A (ja) | 2012-06-21 | 2025-07-10 | ペプチドコンジュゲート粒子 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019016132A Active JP7210306B2 (ja) | 2012-06-21 | 2019-01-31 | ペプチドコンジュゲート粒子 |
| JP2021095735A Active JP7491869B2 (ja) | 2012-06-21 | 2021-06-08 | ペプチドコンジュゲート粒子 |
| JP2023118971A Pending JP2023153869A (ja) | 2012-06-21 | 2023-07-21 | ペプチドコンジュゲート粒子 |
| JP2025116638A Pending JP2025163048A (ja) | 2012-06-21 | 2025-07-10 | ペプチドコンジュゲート粒子 |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10201596B2 (enExample) |
| EP (2) | EP2863942B1 (enExample) |
| JP (5) | JP6557140B2 (enExample) |
| KR (5) | KR20250052503A (enExample) |
| CN (2) | CN104684578B (enExample) |
| AU (5) | AU2013278056B2 (enExample) |
| BR (1) | BR112014032207B1 (enExample) |
| CA (2) | CA2876495C (enExample) |
| DK (1) | DK2863942T3 (enExample) |
| ES (1) | ES2738481T3 (enExample) |
| HR (1) | HRP20191178T1 (enExample) |
| IL (3) | IL236191B (enExample) |
| MX (1) | MX363889B (enExample) |
| PL (1) | PL2863942T3 (enExample) |
| PT (1) | PT2863942T (enExample) |
| RU (1) | RU2669346C2 (enExample) |
| TR (1) | TR201909998T4 (enExample) |
| WO (1) | WO2013192532A2 (enExample) |
| ZA (1) | ZA201409305B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5909745B2 (ja) | 2010-11-12 | 2016-04-27 | クール ファーマシューティカルズ ディベロップメント カンパニー | 炎症性疾患の治療薬、ならびにウイルスまたは細菌感染疾患の治療薬 |
| US9597385B2 (en) | 2012-04-23 | 2017-03-21 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
| KR20250052503A (ko) | 2012-06-21 | 2025-04-18 | 노쓰웨스턴유니버시티 | 펩티드 접합된 입자 |
| CA2932532C (en) | 2012-12-04 | 2021-06-22 | Phosphorex, Inc. | Microparticles and nanoparticles having negative surface charges |
| HK1220368A1 (zh) | 2013-03-13 | 2017-05-05 | Cour Pharmaceuticals Development Company | 用於治疗炎症的免疫修饰性颗粒 |
| EP3760223A1 (en) | 2013-04-03 | 2021-01-06 | N-Fold Llc | Nanoparticle composition for desensitizing a subject to peanut allergens |
| JP6553033B2 (ja) | 2013-08-13 | 2019-07-31 | ノースウェスタン ユニバーシティ | ペプチドコンジュゲート粒子 |
| AU2016379413B2 (en) * | 2015-12-23 | 2024-04-04 | Cour Pharmaceuticals Development Company Inc. | Covalent polymer-antigen conjugated particles |
| US20190365656A1 (en) * | 2016-01-04 | 2019-12-05 | Cour Pharmaceuticals Development Company, Inc. | Particles encapsulating fusion proteins containing linked epitopes |
| GB2550586A (en) | 2016-05-23 | 2017-11-29 | A-Fax Ltd | Racking protection device |
| WO2019217661A1 (en) * | 2018-05-09 | 2019-11-14 | Yale University | Compositions and systems for ex vivo cell modulation and methods of use thereof |
| JP2021523151A (ja) * | 2018-05-11 | 2021-09-02 | ホスホレックス、インコーポレイテッド | 負の表面電荷を有するマイクロ粒子及びナノ粒子 |
| US20210186880A1 (en) * | 2018-08-03 | 2021-06-24 | Brown University | Oral formulations with increased uptake |
| WO2021231898A2 (en) * | 2020-05-14 | 2021-11-18 | Op-T Llc | Nanoparticle compositions and uses thereof |
| JP2023534011A (ja) * | 2020-07-14 | 2023-08-07 | コーニング インコーポレイテッド | 迅速に溶解する細胞培養培地粉末及びその製造方法 |
| MX2024004851A (es) | 2021-10-21 | 2024-06-12 | Cour Pharmaceuticals Dev Company Inc | Tratamiento de cirrosis biliar primaria (pbc) con nanoparticulas tolerizantes. |
| AU2023314797A1 (en) | 2022-07-29 | 2024-12-12 | Repertoire Immune Medicines, Inc. | T cell epitopes associated with type 1 diabetes |
| WO2024243410A1 (en) | 2023-05-23 | 2024-11-28 | Cour Pharmaceuticals Development Company Inc. | Preparation of tolerizing nanoparticles for the treatment of primary biliary cholangitis |
| TW202500576A (zh) | 2023-05-25 | 2025-01-01 | 美商庫爾製藥發展公司股份有限公司 | 以免疫耐受性(tolerizing)奈米粒子治療1型糖尿病(t1d) |
| WO2025072849A1 (en) | 2023-09-29 | 2025-04-03 | Repertoire Immune Medicines, Inc. | Mhc-presentable peptides associated with type 1 diabetes |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4565696A (en) * | 1983-08-03 | 1986-01-21 | The Regents Of The University Of California | Production of immunogens by antigen conjugation to liposomes |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| EP0627933B1 (en) | 1992-02-28 | 2002-11-27 | Autoimmune, Inc. | Bystander suppression of autoimmune diseases |
| US6004763A (en) | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
| FR2695563B1 (fr) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
| JPH06157592A (ja) | 1992-11-24 | 1994-06-03 | Hitachi Chem Co Ltd | ペプチドもしくはその誘導体、それらとタンパク質との結合体、及びこれらを免疫源とする抗エンドセリン−１抗体の製造方法 |
| WO1994027634A1 (en) | 1993-06-02 | 1994-12-08 | Institute For Child Health Research | Cryptic peptides for use in inducing immunologic tolerance |
| US5804201A (en) | 1996-03-11 | 1998-09-08 | The Rockefeller University | Immunomodulatory peptides of vespid antigen 5 |
| JP4085341B2 (ja) | 1997-03-31 | 2008-05-14 | ザ、リージエンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン | 開いたポアの生分解性マトリックス |
| US7427602B1 (en) | 1998-05-13 | 2008-09-23 | The Regents Of The University Of Michigan | Sustained DNA delivery from structural matrices |
| EP1212086B8 (en) | 1999-08-18 | 2008-01-02 | Industry-Academic Cooperation Foundation, The Catholic University of Korea | Immunological tolerance-induction agent |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| US7332168B2 (en) | 2000-08-22 | 2008-02-19 | Micromet Ag | Composition for the elimination of autoreactive B-cells |
| US7029697B2 (en) | 2001-02-14 | 2006-04-18 | Northwestern University | Controlled surface-associated delivery of genes and oligonucleotides |
| US6890556B1 (en) | 2001-02-14 | 2005-05-10 | Northwestern University | Controlled surface-associated delivery of genes and oligonucleotides |
| CN100354297C (zh) * | 2001-10-03 | 2007-12-12 | 希龙公司 | 辅助的脑膜炎球菌组合物 |
| EP1458361A4 (en) | 2001-11-20 | 2007-04-25 | Advanced Inhalation Res Inc | COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT |
| AU2003216851B2 (en) | 2002-03-19 | 2008-04-17 | Powderject Research Limited | Imidazoquinoline adjuvants for vaccines |
| EP1531795A4 (en) | 2002-05-02 | 2011-02-23 | Harvard College | FORMULATIONS FOR LIMITING THE RETENTION OF LUNG INFECTIONS |
| US20040115216A1 (en) | 2002-07-12 | 2004-06-17 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
| US7465463B2 (en) | 2002-09-04 | 2008-12-16 | Polyheal, Ltd. | Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues |
| WO2004053056A2 (en) * | 2002-09-24 | 2004-06-24 | University Of Kentucky Research Foundation | Nanoparticle-based vaccine delivery system containing adjuvant |
| WO2005000272A1 (en) | 2003-06-04 | 2005-01-06 | Isis Pharmaceuticals, Inc. | Long-circulating liposomal compositions |
| WO2005015160A2 (en) | 2003-08-07 | 2005-02-17 | The Children's Hospital Of Philadelphia | Functionalized polymeric colloids |
| WO2005019429A2 (en) | 2003-08-22 | 2005-03-03 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
| US9149440B2 (en) | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
| US20070275007A1 (en) | 2003-11-05 | 2007-11-29 | The Government Of The United States Of America, Represented By The Secretary Of Health And Human S | Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer |
| EP1547581A1 (en) * | 2003-12-23 | 2005-06-29 | Vectron Therapeutics AG | Liposomal vaccine for the treatment of human hematological malignancies |
| ES2246695B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico. |
| US7846466B2 (en) | 2004-06-10 | 2010-12-07 | Northwestern University | Biodegradable scaffolds and uses thereof |
| EP1768692B8 (en) | 2004-07-01 | 2015-06-17 | Yale University | Targeted and high density drug loaded polymeric materials |
| JP2006248978A (ja) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| AU2006282042B2 (en) | 2005-06-17 | 2011-12-22 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials |
| JP2008544049A (ja) | 2005-07-01 | 2008-12-04 | エフ．ホフマン−ラ ロシュ アーゲー | カルボキシル化されたラテックス粒子 |
| WO2007008755A2 (en) | 2005-07-08 | 2007-01-18 | The Board Of Regents, The University Of Texas System | Surface functionalization of polymeric materials |
| GB0514262D0 (en) | 2005-07-12 | 2005-08-17 | Renovo Ltd | Promotion of epithelial regeneration |
| US20070041934A1 (en) | 2005-08-12 | 2007-02-22 | Regents Of The University Of Michigan | Dendrimer based compositions and methods of using the same |
| US20100028450A1 (en) | 2006-01-25 | 2010-02-04 | The Board Of Trustees Of The University Of Illinoi S | Tolerogenic biodegradable artificial antigen presenting system |
| WO2007094003A2 (en) | 2006-02-15 | 2007-08-23 | Ramot At Tel Aviv University Ltd. | Viral display vehicles for treating multiple sclerosis |
| CA2643322C (en) * | 2006-02-24 | 2015-07-21 | Novartis Ag | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions |
| US20090325931A1 (en) | 2006-07-28 | 2009-12-31 | University Court Of The University Of Edinburgh | Use of cdk inhibitors for the treatment of granulocyte mediated disorders |
| AU2007306936B2 (en) | 2006-10-12 | 2014-02-06 | The University Of Queensland | Compositions and methods for modulating immune responses |
| US20090214474A1 (en) | 2006-11-01 | 2009-08-27 | Barbara Brooke Jennings | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| KR101489830B1 (ko) | 2006-12-18 | 2015-02-04 | 콜로로삐아 이탈리아 에스.피.에이 | 발열요법에 적용하기 위한 자성 나노 입자, 그의 제조 및 약리 적용을 갖는 구조체에의 용도 |
| DK2131856T3 (da) | 2007-03-07 | 2014-12-15 | Uti Limited Partnership | Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande |
| US20080311140A1 (en) | 2007-05-29 | 2008-12-18 | Baylor College Of Medicine | Antigen specific immunosuppression by dendritic cell therapy |
| KR20100083150A (ko) * | 2007-09-18 | 2010-07-21 | 리고사이트 파머슈티컬즈 인코퍼레이티드 | 노로바이러스에 대한 보호면역반응을 제공하는 방법 |
| BRPI0817664A2 (pt) * | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo |
| WO2009049365A1 (en) | 2007-10-15 | 2009-04-23 | Cooperative Research Centre For Asthma | A method of prophylaxis and agents for use therein |
| WO2009052561A1 (en) | 2007-10-22 | 2009-04-30 | The Walter And Eliza Hall Institute Of Medical Research | Compositions and methods for manipulating an immune response |
| EP2057998A1 (en) | 2007-10-31 | 2009-05-13 | Universitätsklinikum Hamburg-Eppendorf | Use of modified cells for the treatment of multiple sclerosis |
| US20090123509A1 (en) | 2007-11-08 | 2009-05-14 | Cory Berkland | Biodegradable Colloidal Gels as Moldable Tissue Engineering Scaffolds |
| US20090238879A1 (en) | 2008-01-24 | 2009-09-24 | Northwestern University | Delivery scaffolds and related methods of use |
| CA2722184A1 (en) | 2008-04-25 | 2009-10-29 | Duke University | Regulatory b cells and their uses |
| EP2123261A1 (en) | 2008-05-20 | 2009-11-25 | Stallergenes S.A. | Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance |
| US20110206773A1 (en) | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
| US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
| CA2738855A1 (en) | 2008-09-29 | 2010-04-01 | The Corporation Of Mercer University | Nanospheres encapsulating bioactive material and method for formulation of nanospheres |
| AU2009298112B2 (en) | 2008-10-02 | 2015-11-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Administration of an adsorbent polymer for treatment of systemic inflammation |
| PT2367561E (pt) | 2008-11-30 | 2015-10-23 | Immusant Inc | Composições e métodos para o tratamento da doença celíaca |
| CA2746124A1 (en) | 2008-12-11 | 2010-06-17 | The Governors Of The University Of Alberta | Methods and systems for inducing immunologic tolerance to non-self antigens |
| CA2750098A1 (en) | 2009-01-20 | 2010-07-29 | Myelin Repair Foundation, Inc. | Compositions and methods for induction of antigen-specific tolerance |
| EP2255831A1 (en) | 2009-05-25 | 2010-12-01 | Institut Pasteur | Liposome based diepitope constructs |
| WO2010138193A2 (en) | 2009-05-27 | 2010-12-02 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| US20110135744A1 (en) | 2009-12-03 | 2011-06-09 | The Regents Of The University Of California | Nanoparticle Based Therapy for Dispersing Mucin |
| CN102834112B (zh) | 2010-02-22 | 2016-02-24 | 流体科技公司 | 多糖颗粒疫苗 |
| WO2011119262A1 (en) | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
| WO2011133617A1 (en) | 2010-04-23 | 2011-10-27 | The Board Of Trustees Of The University Of Illinois | Nano-hybrid delivery system for sequential utilization of passive and active targeting |
| WO2011153532A1 (en) | 2010-06-04 | 2011-12-08 | Flow Pharma Inc. | Peptide particle formulation |
| JP5703372B2 (ja) * | 2010-06-04 | 2015-04-15 | トンジ ユニバーシティＴｏｎｇｊｉ Ｕｎｉｖｅｒｓｉｔｙ | ピレンおよびピロールのコポリマーならびに該コポリマーの生成方法 |
| CN107441480A (zh) | 2010-06-30 | 2017-12-08 | 卡姆普根有限公司 | 多肽及其作为用于治疗多发性硬化、类风湿性关节炎以及其他自身免疫病症的药物的用途 |
| US9522183B2 (en) | 2010-07-31 | 2016-12-20 | The Scripps Research Institute | Compositions and methods for inducing immune tolerance |
| US10131875B2 (en) | 2010-08-04 | 2018-11-20 | Duke University | Regulatory B cells and their uses |
| JP5909745B2 (ja) | 2010-11-12 | 2016-04-27 | クール ファーマシューティカルズ ディベロップメント カンパニー | 炎症性疾患の治療薬、ならびにウイルスまたは細菌感染疾患の治療薬 |
| SG10201509138XA (en) | 2010-11-24 | 2015-12-30 | Univ Nanyang Tech | Method for coating particles with calcium phosphate and particles, microparticles and nanoparticles formed thereof |
| US10064406B2 (en) | 2011-01-06 | 2018-09-04 | Cytosorbents Corporation | Polymeric sorbent for removal of impurities from whole blood and blood products |
| ES2712779T3 (es) | 2011-01-24 | 2019-05-14 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Nanopartículas para la administración dérmica y sistémica de fármacos |
| CN103501812A (zh) | 2011-04-29 | 2014-01-08 | 西莱克塔生物科技公司 | 用于过敏症治疗的致耐受性合成纳米载体 |
| CN109172819A (zh) | 2011-07-29 | 2019-01-11 | 西莱克塔生物科技公司 | 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体 |
| US20130058970A1 (en) | 2011-09-06 | 2013-03-07 | Selecta Biosciences, Inc. | Induced tolerogenic dendritic cells to reduce systemic inflammatory cytokines |
| WO2013115965A1 (en) | 2012-01-31 | 2013-08-08 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
| KR20250052503A (ko) * | 2012-06-21 | 2025-04-18 | 노쓰웨스턴유니버시티 | 펩티드 접합된 입자 |
| HK1220368A1 (zh) | 2013-03-13 | 2017-05-05 | Cour Pharmaceuticals Development Company | 用於治疗炎症的免疫修饰性颗粒 |
| JP6553033B2 (ja) | 2013-08-13 | 2019-07-31 | ノースウェスタン ユニバーシティ | ペプチドコンジュゲート粒子 |
-
2013
- 2013-06-21 KR KR1020257011901A patent/KR20250052503A/ko active Pending
- 2013-06-21 KR KR1020217023650A patent/KR20210096312A/ko not_active Ceased
- 2013-06-21 JP JP2015518611A patent/JP6557140B2/ja active Active
- 2013-06-21 BR BR112014032207-4A patent/BR112014032207B1/pt active IP Right Grant
- 2013-06-21 US US14/410,011 patent/US10201596B2/en active Active
- 2013-06-21 CA CA2876495A patent/CA2876495C/en active Active
- 2013-06-21 DK DK13807832.4T patent/DK2863942T3/da active
- 2013-06-21 WO PCT/US2013/047079 patent/WO2013192532A2/en not_active Ceased
- 2013-06-21 KR KR1020157001460A patent/KR102139267B1/ko active Active
- 2013-06-21 RU RU2015101758A patent/RU2669346C2/ru active
- 2013-06-21 KR KR1020227042654A patent/KR20220166879A/ko not_active Ceased
- 2013-06-21 HR HRP20191178TT patent/HRP20191178T1/hr unknown
- 2013-06-21 TR TR2019/09998T patent/TR201909998T4/tr unknown
- 2013-06-21 MX MX2014015843A patent/MX363889B/es active IP Right Grant
- 2013-06-21 CA CA3211102A patent/CA3211102A1/en active Pending
- 2013-06-21 PL PL13807832T patent/PL2863942T3/pl unknown
- 2013-06-21 EP EP13807832.4A patent/EP2863942B1/en active Active
- 2013-06-21 CN CN201380041634.5A patent/CN104684578B/zh active Active
- 2013-06-21 EP EP19168035.4A patent/EP3607973A1/en active Pending
- 2013-06-21 ES ES13807832T patent/ES2738481T3/es active Active
- 2013-06-21 PT PT13807832T patent/PT2863942T/pt unknown
- 2013-06-21 AU AU2013278056A patent/AU2013278056B2/en active Active
- 2013-06-21 KR KR1020207021560A patent/KR102283760B1/ko active Active
- 2013-06-21 CN CN201910226407.9A patent/CN110064049B/zh active Active
-
2014
- 2014-12-11 IL IL236191A patent/IL236191B/en active IP Right Grant
- 2014-12-17 ZA ZA2014/09305A patent/ZA201409305B/en unknown
-
2018
- 2018-09-28 AU AU2018236881A patent/AU2018236881B2/en active Active
-
2019
- 2019-01-31 JP JP2019016132A patent/JP7210306B2/ja active Active
- 2019-02-11 US US16/272,775 patent/US11413337B2/en active Active
- 2019-05-26 IL IL266880A patent/IL266880B/en unknown
-
2020
- 2020-04-17 US US16/852,196 patent/US11826407B2/en active Active
- 2020-06-12 AU AU2020203884A patent/AU2020203884A1/en not_active Abandoned
- 2020-09-30 AU AU2020244453A patent/AU2020244453B2/en active Active
-
2021
- 2021-06-08 JP JP2021095735A patent/JP7491869B2/ja active Active
-
2022
- 2022-02-24 IL IL290884A patent/IL290884B1/en unknown
-
2023
- 2023-07-21 JP JP2023118971A patent/JP2023153869A/ja active Pending
- 2023-11-13 US US18/507,837 patent/US20240082371A1/en not_active Abandoned
-
2024
- 2024-09-18 US US18/889,061 patent/US20250009858A1/en active Pending
-
2025
- 2025-05-12 AU AU2025203403A patent/AU2025203403A1/en active Pending
- 2025-07-10 JP JP2025116638A patent/JP2025163048A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522569A5 (enExample) | ||
| RU2015101758A (ru) | Частицы, конъюгированные с пептидами | |
| JP2012515722A5 (enExample) | ||
| CN113332422B (zh) | 肽缀合颗粒 | |
| JP2022173236A (ja) | 安定した過飽和状態でラパマイシンをもつ合成ナノキャリアに関する方法および組成物 | |
| JP2022101576A (ja) | スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子） | |
| JP2017122110A5 (enExample) | ||
| JP2014514335A5 (enExample) | ||
| JP2014514331A5 (enExample) | ||
| JP2016524599A5 (enExample) | ||
| JP5642665B2 (ja) | 抗原特異的免疫寛容を誘導するための粘膜付着性粒子状製剤 | |
| CN116966162A (zh) | 用于治疗炎症的免疫修饰性颗粒 | |
| RS65941B1 (sr) | Formulacije i doze pegilovane urikaze | |
| CN105338968A (zh) | 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体 | |
| CN116568329A (zh) | 用于降低针对免疫球蛋白蛋白酶的免疫应答的组合物 | |
| KR20220146559A (ko) | 면역억제제를 포함하는 합성 나노담체를 사용하는 방법 및 조성물 | |
| JP2020513420A (ja) | 負の表面電荷を有するマイクロ粒子及びナノ粒子 | |
| Paris et al. | New therapeutic approaches for allergy: a review of cell therapy and bio-or nano-material-based strategies | |
| WO2020210843A2 (en) | Tolerogenic artificial antigen-presenting cells | |
| Roman et al. | Intradermal immunization with ovalbumin‐loaded poly‐ɛ‐caprolactone microparticles conferred protection in ovalbumin‐sensitized allergic mice | |
| CN113925960A (zh) | 一种预防或治疗i型糖尿病的疫苗系统及其制备方法 | |
| Woo et al. | Combined poly (lactide-co-glycolide) microspheres containing diphtheria toxoid for a single-shot immunization | |
| Arthanari et al. | Preparation and evaluation of sucrose stabilized tetanus toxoid encapsulated into chitosan microspheres | |
| HK40058733A (zh) | 肽缀合颗粒 | |
| WO2024229380A1 (en) | Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases |